Viking Therapeutics (VKTX) Financials

Viking Therapeutics (NASDAQ: VKTX) remains in a classic clinical-stage biotech profile: no revenue, significant R&D spending, recurring net losses, and a balance sheet that is being used to fund pipeline development rather than operations. The latest quarter, Q1 2026, shows the company is still burning cash, but it also continues to maintain a very large liquidity cushion.

• Very strong liquidity position: VKTX ended Q1 2026 with $602.96 million in cash, equivalents, and short-term investments, which is a sizable war chest for a biotech with no revenue.
• Balance sheet remains net cash positive: Total assets of $608.24 million versus total liabilities of just $106.33 million leaves shareholders with $501.92 million in equity.
• Quarterly cash generation from investing activity helped offset burn: The company posted $54.19 million of net cash from investing activities in Q1 2026, driven by sales/maturities of investments exceeding purchases.
• Interest and investment income is meaningful: VKTX generated $5.8 million in interest and investment income in Q1 2026, helping partially offset operating losses.
• Share dilution appears modest in the near term: Weighted average diluted shares in Q1 2026 were 115.6 million, only slightly above prior periods, suggesting limited immediate dilution.
• Operating expenses remain heavily weighted toward R&D: Q1 2026 R&D spending was $150.15 million versus $13.98 million of SG&A, consistent with a pipeline-focused strategy.
• The company still has no product revenue: Q1 2026 revenue was $0, so the business continues to depend on capital markets and investment income.
• Non-cash and working-capital items helped the cash flow picture somewhat: Q1 2026 had $11.27 million in non-cash adjustments and $34.28 million in operating asset/liability changes, partially cushioning the operating loss.
• Operating losses remain very large: Q1 2026 net loss was $158.33 million, and operating loss was $164.13 million.
• Cash burn is still substantial: Net cash from operating activities was negative $113.98 million in Q1 2026, indicating the company is still consuming cash quickly.
• Cash balance declined during the quarter: Net change in cash and equivalents was negative $47.71 million in Q1 2026.
• Pre-approval biotech risk remains high: With no revenue and large ongoing R&D outlays, valuation will continue to depend heavily on clinical progress and financing markets rather than current earnings power.

Looking at the last four years, the most important trend is that VKTX has steadily scaled up spending as it advances its pipeline. Quarterly operating losses moved from roughly $20 million to $34 million in early 2023/2024, then jumped sharply in 2025 and 2026 to the $75 million to $164 million range as development costs increased. That’s not unusual for a biotech, but it does mean the company’s future depends on clinical execution and eventual commercialization, not near-term profitability.

The balance sheet, however, has been a major strength. Cash and investments were above $900 million in parts of 2024 and still stood at just over $600 million in Q1 2026. Even after years of heavy spending, Viking Therapeutics still has enough liquidity to fund ongoing programs for some time. For investors, the key question is whether that cash gets translated into meaningful clinical wins before the balance sheet is meaningfully depleted.